Why not every cancer therapy works the same way for every patient, a look behind the scenes of tumor biology

"Why does the treatment work so well for my neighbor, but barely for me?" This is a question we hear often at UNIFONTIS, under the leadership of Prof. Dr. med. Joachim Drevs. The answer rarely lies in the treatment alone, but above all in the tumor itself. Anyone who understands what is really happening at the cellular level also understands why two people with the same diagnosis can respond differently to the same therapy. In this article, we take you behind the scenes of tumor biology.
A tumor is not a uniform structure
Within a single tumor, there are often many different cell populations that differ genetically from one another. Experts refer to this as intratumoral heterogeneity. This means that even within the same tumor, not all cells respond to a drug in the same way. While some of the cells respond to a therapy, another part may be less sensitive or may even continue growing unaffected. This finding is one of the reasons why a treatment that initially works well can lose its effect over time.
Tumors change while therapy is ongoing
A tumor is not a rigid object, but rather an evolving biological system. Under the pressure of therapy, tumor cells can adapt, develop new characteristics, and build up resistance. This process is known as clonal evolution. This becomes especially clear in advanced diseases, where the biological properties of the tumor can shift over the course of treatment.
This is exactly where one of Prof. Drevs' research focuses comes in, the study of circulating tumor cells. These are tumor cells that have detached from the surrounding tissue and can be detected in the blood. Analyzing them can provide clues about how a tumor changes biologically over the course of treatment, and can help adjust a therapy at an early stage, before visible changes appear on imaging. Prof. Drevs has conducted research in this area, among other things, on advanced pancreatic cancer and metastatic colorectal cancer. This work shows, as an example, why cancer therapy should be adjusted over time rather than treated as a one-time decision.
Why the tumor's blood supply also plays a role
Another building block of tumor biology concerns the blood vessel supply. For a tumor to grow, it must connect itself to the blood vessel system, a process known as angiogenesis. How strongly and how chaotically a tumor forms new blood vessels affects not only its growth, but also how well medications can actually reach the tumor tissue in the first place. A tumor with a chaotic vascular structure may absorb active substances less effectively than a tumor with a more regular blood supply. This, too, explains why one and the same medication can work differently well in different patients.
Early in his scientific career, Prof. Drevs already focused intensively on research into angiogenesis inhibitors, meaning active substances that specifically interfere with the blood vessel growth of tumors. This research experience, gathered over many years, flows directly into UNIFONTIS' assessment of which therapy components may make sense for a patient's individual tumor biology.
What these findings mean for treatment
Because tumors differ at the cellular level, change over time, and have different blood supplies, a rigid treatment scheme can only partially account for these particular features. At UNIFONTIS in Sickte, we therefore include not only classic diagnostics but also progress parameters, such as the individual immune profile, in therapy planning, and we regularly check whether an adjustment might make sense. In this way, a therapy concept can be developed that fits the biological reality of the respective tumor, not only at the start, but throughout the entire course of treatment.
What matters to us here is a realistic assessment: adjusting therapy based on biological progress parameters can help guide treatment more precisely, but it cannot guarantee a specific response or a specific course of disease, since tumor biology differs from person to person and cannot be fully predicted.
Looking behind the scenes is worthwhile!
Tumor biology provides an important explanation for why cancer therapies can work so differently, even in comparable diagnoses. A tumor consists of different cell populations, changes over time, and is connected to the vascular system in different ways. For us at UNIFONTIS, taking these biological relationships seriously means not making therapy decisions just once, but reviewing them again and again in light of new findings and progress observations.
If needed, you are welcome to schedule an appointment at our practice through our contact page.
Sources and further information
Information and therapy concept of the practice: unifontis.net
Scientific publications by Prof. Dr. med. Joachim Drevs, including on circulating tumor cells and angiogenesis inhibitors: PubMed

